Jade Biosciences, Inc. Debt Securities, Trading, Unrealized Gain (Loss)
Jade Biosciences, Inc. (JBIO) reported Debt Securities, Trading, Unrealized Gain (Loss) of -$245.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesTradingUnrealizedGainLoss · last filed 2026-08-10
- Jade Biosciences, Inc. debt securities, trading, unrealized gain (loss) for the quarter ending 2026-06-30 was -$245.00K.
- Jade Biosciences, Inc. debt securities, trading, unrealized gain (loss) for the quarter ending 2026-03-31 was -$473.00K.
- Jade Biosciences, Inc. debt securities, trading, unrealized gain (loss) for the quarter ending 2025-06-30 was $0.00.
- Jade Biosciences, Inc. debt securities, trading, unrealized gain (loss) for the quarter ending 2025-03-31 was $0.00.
- Jade Biosciences, Inc. debt securities, trading, unrealized gain (loss) for fiscal 2025 was $157.00K.
- Jade Biosciences, Inc. debt securities, trading, unrealized gain (loss) for fiscal 2024 was -$132.00K, a 118.78% decline from fiscal 2023.
- Jade Biosciences, Inc. debt securities, trading, unrealized gain (loss) for fiscal 2023 was $703.00K.
- Jade Biosciences, Inc. debt securities, trading, unrealized gain (loss) for fiscal 2022 was -$407.00K.
| Period end | Debt Securities, Trading, Unrealized Gain (Loss) 3 month | Debt Securities, Trading, Unrealized Gain (Loss) 3 month as first filed | Debt Securities, Trading, Unrealized Gain (Loss) 6 month | Debt Securities, Trading, Unrealized Gain (Loss) 9 month | Debt Securities, Trading, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$245.00K 10-Q · filed 2026-08-10 | -$718.00K 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | -$473.00K 10-Q · filed 2026-05-07 | ||||
| 2025-12-31 | $157.00K 10-K · filed 2026-03-06 | ||||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-10 | $0.00 10-Q · filed 2026-08-10 | -$119.00K derived: sum of 3 quarters · filed 2026-08-10 | $188.00K derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | -$55.00K 10-Q · filed 2025-04-25 | -$119.00K derived: sum of 2 quarters · filed 2026-05-07 | $188.00K derived: sum of 3 quarters · filed 2026-05-07 | $138.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $0.00 10-K · filed 2026-03-06 | $138.00K derived: sum of 3 quarters · filed 2025-03-27 | -$132.00K 10-K · filed 2025-03-27 | |
| 2024-09-30 | $307.00K 10-Q · filed 2024-11-12 | $257.00K derived: sum of 2 quarters · filed 2024-11-12 | -$13.00K 10-Q · filed 2024-11-12 | $447.00K derived: sum of 4 quarters · filed 2025-04-25 | |
| 2024-06-30 | -$50.00K 10-Q · filed 2024-08-12 | -$320.00K 10-Q · filed 2024-08-12 | $140.00K derived: sum of 3 quarters · filed 2025-04-25 | $118.00K derived: sum of 4 quarters · filed 2025-04-25 | |
| 2024-03-31 | -$270.00K 10-Q · filed 2025-04-25 | $190.00K derived: sum of 2 quarters · filed 2025-04-25 | $168.00K derived: sum of 3 quarters · filed 2025-04-25 | $146.00K derived: sum of 4 quarters · filed 2025-04-25 | |
| 2023-12-31 | $460.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $438.00K derived: sum of 2 quarters · filed 2025-03-27 | $416.00K derived: sum of 3 quarters · filed 2025-03-27 | $703.00K 10-K · filed 2025-03-27 | |
| 2023-09-30 | -$22.00K 10-Q · filed 2024-11-12 | -$44.00K derived: sum of 2 quarters · filed 2024-11-12 | $243.00K 10-Q · filed 2024-11-12 | $526.00K derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | -$22.00K 10-Q · filed 2024-08-12 | $243.00K 10-Q · filed 2024-08-12 | $548.00K derived: sum of 3 quarters · filed 2024-08-12 | $562.00K derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $265.00K 10-Q · filed 2024-05-13 | $570.00K derived: sum of 2 quarters · filed 2024-05-13 | $584.00K derived: sum of 3 quarters · filed 2024-05-13 | $443.00K derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $305.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $319.00K derived: sum of 2 quarters · filed 2024-03-25 | $178.00K derived: sum of 3 quarters · filed 2024-03-25 | -$407.00K 10-K · filed 2024-03-25 | |
| 2022-09-30 | $14.00K 10-Q · filed 2023-11-13 | -$127.00K derived: sum of 2 quarters · filed 2023-11-13 | -$712.00K 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | -$141.00K 10-Q · filed 2023-08-14 | -$726.00K 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$585.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |